

De Novo Mutations in the Sodium-Channel Gene *SCN1A* Cause Severe Myoclonic Epilepsy of Infancy

Lieve Claes,¹ Jurgen Del-Favero,¹ Bertien Ceulemans,^{2,3} Lieven Lagae,^{3,4} Christine Van Broeckhoven,¹ and Peter De Jonghe^{1,2}

¹Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Antwerp, and ²Department of Neurology, University Hospital Antwerp, Antwerp; ³Epilepsy Center for Children and Youth, Pulderbos, Belgium; and ⁴Department of Child Neurology, University Hospital Gasthuisberg, Leuven, Belgium

Severe myoclonic epilepsy of infancy (SMEI) is a rare disorder that occurs in isolated patients. The disease is characterized by generalized tonic, clonic, and tonic-clonic seizures that are initially induced by fever and begin during the first year of life. Later, patients also manifest other seizure types, including absence, myoclonic, and simple and complex partial seizures. Psychomotor development stagnates around the second year of life. Missense mutations in the gene that codes for a neuronal voltage-gated sodium-channel α -subunit (*SCN1A*) were identified in families with generalized epilepsy with febrile seizures plus (GEFS+). GEFS+ is a mild type of epilepsy associated with febrile and afebrile seizures. Because both GEFS+ and SMEI involve fever-associated seizures, we screened seven unrelated patients with SMEI for mutations in *SCN1A*. We identified a mutation in each patient: four had frameshift mutations, one had a nonsense mutation, one had a splice-donor mutation, and one had a missense mutation. All mutations are de novo mutations and were not observed in 184 control chromosomes.

Introduction

Severe myoclonic epilepsy of infancy (SMEI) was first described by Dravet in 1978 and is included as an epileptic syndrome in the International League Against Epilepsy (ILAE) classification, which was proposed by the Commission on Classification and Terminology of the ILAE (1989). Early manifestations of the disease are tonic, clonic, and tonic-clonic seizures that occur within the first year of life. These seizures are often prolonged, generalized, and associated with fever. Later in life, patients with SMEI have afebrile seizures, including myoclonic, tonic-clonic, absence, and simple and complex partial seizures. Early psychomotor and speech development is normal, but developmental stagnation occurs during the second year of life. Patients often become ataxic, and speech development is delayed. In general, SMEI is very resistant to all forms of pharmacotherapy.

A mild phenotype characterized by febrile seizures and, occasionally, epilepsy in adulthood was described by Scheffer and Berkovic (1997) as “generalized epilepsy with febrile seizures plus” (GEFS+) (MIM 604233). Two families with GEFS+ were re-

ported to segregate missense mutations in the gene that codes for the α -subunit of a neuronal voltage-gated sodium channel (*SCN1A*) located on chromosome 2q (Escayg et al. 2000). Both mutations are within the transmembrane segments DII S4 and DIV S4 (fig. 1), which are voltage sensors of the channel. Recently, additional families with GEFS+ were reported to have novel missense mutations in *SCN1A* (Escayg et al. 2001; Wallace et al. 2001), which were located in the linker between DII and DIII and in the DI S2-S3 loop, DIII S5, and DIV S4 (fig. 1).

Because fever-induced seizures occur both in GEFS+ and SMEI, we screened *SCN1A* for mutations in seven patients with SMEI.

Subjects and Methods

Subjects

We studied seven Belgian patients with SMEI, diagnosed according to the criteria of the Commission on Classification and Terminology of the ILAE (1989). DNA was extracted from peripheral blood of the seven patients, their unaffected parents, and 92 healthy control persons randomly selected from the Belgian population. The study was approved by the Commission for Medical Ethics of the University of Antwerp.

Human *SCN1A*

We defined the exon-intron boundaries of *SCN1A* by aligning the genomic sequence contained in BAC clone

Received March 9, 2001; accepted for publication April 12, 2001; electronically published May 15, 2001.

Address for correspondence and reprints: Prof. Dr. P. De Jonghe, Laboratory of Molecular Genetics, University of Antwerp (U.I.A.), Department of Biochemistry, Universiteitsplein 1 B-2610 Antwerpen, Belgium. E-mail: dejonghe@uia.ua.ac.be

© 2001 by The American Society of Human Genetics. All rights reserved. 0002-9297/2001/6806-0004\$02.00




Figure 1 Organization of SCN1A. The neuronal voltage-gated sodium-channel α -subunit SCN1A is a monomer and consists of four homologous domains (DI–DIV). Each domain has six transmembrane segments (S1–S6). S4 has several positively charged amino acids and represents the voltage sensor. P = the pore loop, which delineates the pore of the channel. Mutations identified in this study (described in table 2) were denoted as follows: asterisks (*) = deletion, insertion and nonsense mutations; diamond (◆) = missense mutation; circles (●) = GEFS+ missense mutations reported by Escayg et al. (2000, 2001); and squares (■) = GEFS+ missense mutations reported by Wallace et al. (2001).

RP11-2I8 (Genbank accession number AC010127), the cDNA sequence of *SCN8A* (Genbank accession number XM_006838), and the protein sequence of *SCN1A* (Escayg et al. 2000). Recently, the complete cDNA and protein sequence of *SCN1A* was submitted to Genbank (accession numbers AF225985 and AAK00217). This sequence represents an alternatively spliced form of *SCN1A* that was described by Schaller et al. (1992). The

protein sequence published by Escayg et al. (2000) contains an additional 11 amino acids at the 3' end of exon 11, which encode part of the cytoplasmic loop between DI and DII.

Mutation Detection and Molecular-Genetic Analysis

Intronic primer pairs were designed for each of the 26 exons, on the basis of the genomic sequence, using

Table 1

Sequence of the Intronic Primers (5'→3') Used for the Mutation Analysis of *SCN1A*

| Exon | 5' Primer (Forward) | 3' Primer (Reverse) | No. of Base Pairs in PCR Product |
|------|--------------------------|-----------------------------|----------------------------------|
| 1 | TCATGGCACAGTTCCTGTATC | GCAGTAGGCAATTAGCAGCAA | 589 |
| 2 | TGGGGCACTTTAGAAATTGTG | TGACAAAGATGCAAATGAGAG | 391 |
| 3 | GCACTTTGGGCCTTTCAATG | TGAGCATGTCCCTCTTGCTG | 314 |
| 4 | AGGGCTACGTTTCATTTGTATG | TGTGCTAAATTTGGAATCCAGAG | 421 |
| 5 | CAGCTCTTCGCACTTTCAGA | TCAAGCAGAGAAGGATGCTGA | 307 |
| 6 | AGCGTTGCAAACATTCTTGG | GGGATATCCAGCCCTCAAG | 477 |
| 7 | GACAAATACTTGTGCCTTTGAATG | ACATAATCTCATACTTTATCAAAAACC | 362 |
| 8 | GAAATGGAGGTGTTGAAAATGC | AATCCTTGGCATCACTCTGC | 581 |
| 9 | AGTACAGGGTGCTATGACCAAC | TCCTCATAACAACCCTGCTC | 440 |
| 10 | TCTCCAAAAGCCTTCATTAGG | TTCTAATTCTCCCCCTCTCTCC | 544 |
| 11 | TCCTCATTCTTAATCCCAAGG | GCCGTTCTGTAGAAACTGG | 670 |
| 12 | GTCAGAAATATCTGCCATCACC | GAATGCACTATTCCCAACTCAC | 372 |
| 13 | TGGGCTCTATGTGTGTGTCTG | GGAAGCATGAAGGATGGTTG | 543 |
| 14 | TACTTCGCGTTTCCACAAGG | GCTATGCAGAACCCTGATTG | 433 |
| 15 | ATGAGCCTGAGACGGTTAGG | ATACATGTGCCATGCTGGTG | 544 |
| 16 | TGCTGTGGTGTTCCTTCTC | TGTATTCATACTTCCCACACC | 658 |
| 17 | AAAAGGGTTAGCACAGACAATG | ATTGGGCAGATAATCAAAGC | 489 |
| 18 | CACACAGCTGATGAATGTGC | TGAAGGGCTACACTTTCTGG | 567 |
| 19 | TCTGCCCTCTATTCCAATG | GCCCTTGTCTTCCAGAAATG | 445 |
| 20 | AAAATTACATCTTTACATCAAAGT | TTTTGCATGCATAGATTTTCC | 395 |
| 21 | TGAACCTTGCTTTTACATATCC | ACCCATCTGGGCTCATAAAC | 579 |
| 22 | TGCTTGGTCCAAAATCTGTG | TTGGTCGTTTATGCTTTATTCG | 283 |
| 23 | CCCTAAGGCCAATTCAGG | ATTTGGCAGAGAAAACACTCC | 378 |
| 24 | GAGATTTGGGGTGTGTGTC | GGATTGTAATGGGGTGCTTC | 600 |
| 25 | CAAAAATCAGGGCCAATGAC | TGATTGCTGGGATGATCTTG | 483 |
| 26a | AGGACTCTGAACCTTACCTTGG | TGTACATGTTACCACAACCAG | 589 |
| 26b | TGTGGGAACCCATCTGTG | CCATGAATCGCTTCCATC | 418 |
| 26c | TGCTTTTACAAAGCGGTTT | GTTTGTCTGACAAGGGTCCAC | 592 |

Table 2***SCN1A* Mutations in Patients with SMEI**

| Patient Number | Location in <i>SCN1A</i> | DNA Change ^a | Position in <i>SCN1A</i> | Mutation | Protein Change |
|----------------|--------------------------|-------------------------|--------------------------|----------------------------------|----------------|
| EP 153 | Exon 5 | c.657-658delAG | DI S4 | Frameshift, premature stop codon | S219fsX275 |
| EP 78 | Exon 5 | c.664C→T | DI S4 | Premature stop codon | R222X |
| EP 147 | Exon 16 | c.2956C→T | DII S6 | Missense mutation | L986F |
| EP 91 | Exon 16 | c.3299-3300insAA | DII-DIII linker | Frameshift, premature stop codon | K1100fsX1107 |
| EP 64 | Intron 22 | IVS22+1G→A | DIII S5-S6 pore | Splice donor | — |
| EP 90 | Exon 26 | c.5010-5013delGTTT | DIV S4-S5 loop | Frameshift, premature stop codon | L1670fsX1678 |
| EP 89 | Exon 26 | c.5536-5539delAAAC | C-terminal | Frameshift, premature stop codon | S1846fsX1856 |

^a Numbering of mutations started from the initiating ATG codon, as described by Escayg et al. (2000).

the Primer3 program (table 1). Exons and splice-site junctions were amplified using PCR, from 10 ng genomic DNA in a standard PCR procedure that used Platinum *Taq* (Life Technologies). Next, PCR fragments were denatured at 95°C for 4 min, were slowly cooled to room temperature, and subsequently were analyzed by denaturing high performance liquid chromatography (DHPLC) on the WAVE automated instrument (Transgenomic), as described elsewhere (Underhill et al. 1997). Each fragment with an aberrant DHPLC pattern was purified using the PCR product presequencing kit (USB). Subsequently, the products were sequenced using the BigDye Terminator Cycle Sequencing kit (PE Applied Biosystems) and forward and reverse primers. Sequence reactions were performed on an ABI 3700 automated sequencer (PE Applied Biosystems). Data were collected and analyzed using the ABI DNA sequence analysis software, version 3.6.

We used pyrosequencing, as described by Alderborn et al. (2000), or PCR-RFLP analysis to screen the control population for the presence of the *SCN1A* mutations observed in the patients. The following primers were used for pyrosequencing: 5'-AAATCGTCTTCAATGCTCGG-3' (c.657-658delAG), 5'-GAAATCGTCTTCAATG-3' (c.664C→T), 5'-AGAAGCAAGGCCAGAAAG-3' (c.2956C→T), 5'-GTTGAAAATACATTATTG-3' (c.3299-3300insAA), 5'-TGTATGCAGCAGTTGAT-TCC-3' (IVS22+1G→A), and 5'-CAATCTGCCACAAC-CAA-3' (c.5536-5539delAAAC). The restriction enzyme *HincII* was used for the PCR-RFLP, thereby cutting the wild-type 589-bp fragment of exon 26a into fragments of 483 and 106 bp. The c.5010-5013delGTTT mutation creates an extra *HincII* restriction site in exon 26a, and digestion of the fragment results in three fragments, of 254, 225, and 106 bp.

The *SCN1A* mutations were described according to the nomenclature established by den Dunnen and Antonarakis (2000), and numbering was started from the initiating ATG codon, as described by Escayg et al. (2000).

Paternity Testing

We genotyped D21S188, a multiallelic microsatellite marker on chromosome 21p (Wang et al. 1999). This marker shows an average of 16 distinct alleles derived from eight chromosomes. In addition, we genotyped several highly informative microsatellite markers on chromosomes 17 (D17S785, D17S802, and D17S1847) and 18 (D18S51, D18S68, and D18S465). Heterozygosity frequencies of the chromosome 17 and 18 markers are 74%–89% (CEPH genotype database).

Results

SCN1A Mutation Analysis

All 26 exons and exon-intron boundaries of *SCN1A* were analyzed for mutations in seven patients with SMEI by DHPLC analysis of PCR-amplified fragments (table 1). In each patient with SMEI, we observed a single aberrant *SCN1A* fragment (table 2). Subsequent sequence analysis identified a heterozygous mutation in each patient: three out-of-frame deletions; one insertion; and one nonsense, one splice-donor, and one missense mutation (fig. 2). Table 2 summarizes the mutation data, and figure 1 illustrates the location of the mutations within the *SCN1A* protein. The deletions and insertion result in a frameshift with a premature stop codon: c.657-658delAG, c.3299-3300insAA, c.5010-5013delGTTT, and c.5536-5539delAAAC. The 5' splice-site mutation (IVS22+1G→A) most likely leads to either exon skipping or use of a cryptic splice-donor site. A potential splice-donor consensus GT starts at IVS22+45, which, if used, results in a premature stop codon in exon 23. The missense mutation c.2956C→T results in a change from leucine to phenylalanine amino acid. The leucine at codon 986 is highly conserved among paralogical and orthological sodium-channel α -subunits (fig. 3). Most likely the L986F causes severe damage to *SCN1A*.

We used sequencing analysis to determine whether any patient's mutation was present in either of the unaffected parents. In all cases, the mutation was absent from the




Figure 2 Chromatograms of the *SCN1A* mutations in comparison with *SCN1A* wild-type sequences. Exonic sequences are in uppercase; intronic sequences are in lowercase.

parents. Also, for all patients, paternity was confirmed using several microsatellite markers. For each mutation (except for the c.5010-5013delGTTT mutation), we developed a pyrosequencing assay and showed that the mutations were absent from 92 control individuals. The c.5010-5013delGTTT mutation creates a new *HincII* restriction site, and we used PCR-RFLP to show that the mutation was absent in 92 control individuals (data not shown).

Phenotype of Patients with SMEI

Among the seven patients with SMEI, the age at onset of disease was 2–6 mo (table 3). In all patients, the earliest seizures were generalized; in four of the seven patients, these seizures were associated with fever. Subsequent seizures included secondary generalized tonic-clonic, myoclonic, absence, and simple and complex partial seizures. In all patients, the seizures were resistant to therapy. All patients became mentally retarded, and five patients have ataxia. One patient died at the age of 4 years.

Discussion

In seven patients with SMEI, we identified a heterozygous mutation in *SCN1A* that was absent in their parents, thereby providing substantial evidence that (1) SMEI has a genetic etiology and (2) de novo mutations in *SCN1A* are probably a major cause of SMEI. Heterozygous *SCN1A* mutations have also been reported in families with autosomal dominant GEFS+. However, all GEFS+ mutations are missense mutations that display reduced penetrance. In contrast, all cases of SMEI occur in isolated patients. The difference in phenotype and severity is reflected in the nature of *SCN1A* mutations identified in patients with SMEI. In five of seven patients with SMEI, we identified frameshift deletions (c.657-658delAG, c.5010-5013delGTTT, c.5536-5539delAAAC) or an insertion (c.3299-3300insAA) or a nonsense mutation (c.664C→T). Also, in one patient with SMEI, we identified a G→A transition in the conserved GT consensus sequence of the splice-donor site of intron 22. The consequence of this mutation can only be elucidated by analyzing the mutated transcript or protein. In one patient with SMEI, we identified a missense mutation at codon 986 (L986F), which is located within domain DII S6 of the *SCN1A* protein. Since codon 986 is highly conserved among α-subunits of human and other species, it can be predicted that this mutation may have a deleterious effect on *SCN1A*.

Thus, in the majority of patients with SMEI, the mutation results in early termination of translation, thereby producing a C-truncated *SCN1A* protein from one of the *SCN1A* alleles. Rapid degradation of these truncated transcripts or proteins could lead to a loss of function comparable with haploinsufficiency. Alternatively, some of the transcripts could lead to abnormal proteins

| | IIS6 | Accession no. |
|---------------------|---------------------------|---------------|
| Human <i>SCN1A</i> | MCLTVFMMVMVIGNLVVNLFLALLL | AAK00217 |
| Rat <i>scn1a</i> |R..... | AAA79965 |
| Human <i>SCN2A</i> | | NP_066287 |
| Human <i>SCN3A</i> | ..I..L..... | AAK00219 |
| Rat <i>scn3a</i> | ..I...L..... | NP_037251 |
| Human <i>SCN4A</i> |L..... | NP_000325 |
| Human <i>SCN5A</i> | L..L..LL..... | NP_000326 |
| Human <i>SCN6A</i> | W.IPFYL..IL...L..Y.....V- | NP_002967 |
| Human <i>SCN8A</i> | ..I..... | XP_006838 |
| Human <i>SCN9A</i> | ..I.Y..... | NP_002968 |
| Human <i>SCN10A</i> | I..IL.LT..L.....I... | NP_006505 |
| Human <i>SCN11A</i> | L.VI..ILIT..K.....I... | AAF17480 |
| Human <i>SCN12A</i> | L.VI..ILIT..K.....I... | NP_054858 |
| Fugu | ..I..... | BAA07195 |
| Squid | ..VPF.LLT.I..... | AAA16202 |
| Electric Eel | ..A.Y...II.....M..... | CAA25587 |
| <i>Drosophila</i> | S.IPF.LATV..... | AAB59192 |

Figure 3 Evolutionary conservation of *SCN1A*. Sequence alignment and evolutionary conservation of the 986L residue (boxed).

Table 3**Clinical Features of Seven Patients with SMEI with Mutations in *SCN1A***

| PATIENT CHARACTERISTIC | DATA FOR PATIENTS | | | | | | |
|-------------------------|-------------------|----------------|----------|---------|-----------------------------------|----------|----------------------|
| | EP 64 | EP 78 | EP 89 | EP 90 | EP 91 | EP 147 | EP153 |
| Sex | Male | Male | Male | Female | Female | Female | Male |
| Year of birth | 1994 | 1994 | 1988 | 1995 | 1992 | 1998 | 1990 |
| Race | White | White | White | White | White | White | White |
| Status at birth | Normal | Normal | Normal | Normal | Normal | Normal | Normal |
| Family history: | | | | | | | |
| Consanguinity | — | — | — | — | — | — | — |
| Febrile seizures | — | Paternal uncle | — | Mother | — | — | Maternal niece |
| Epilepsy | — | — | — | — | Maternal niece, paternal uncle | — | — |
| First seizure: | | | | | | | |
| Age | 5 mo | 6 mo | 2 mo | 4 mo | 4 mo | 4 mo | 3 mo |
| Type | GTCS | GCS | GTS | GTCS | GCS | GTCS | GTCS |
| Fever-associated | + | — | — | — | + | + | + |
| Other seizures: | | | | | | | |
| Secondary GTCS | + | + | + | + | + | + | + |
| Myoclonic seizures: | + | + | + | + | + | + | + |
| Age at onset | >7 mo | >10 mo | >3 mo | >12 mo | >8 mo | >12 mo | >3 years |
| Frequency | Daily | Daily | Daily | Rarely | Daily | Rarely | Rarely |
| Other seizures | CPS | Abs | — | Abs | — | Abs, SPS | Abs |
| Other features: | | | | | | | |
| Therapy-resistant | + | + | + | + | + | + | + |
| Mental retardation | Moderate | Moderate | Severe | Severe | Severe | Moderate | Moderate |
| Ataxia | ± | + | + | — | — | + | + |
| Age at last examination | 6 years | 6 years | 10 years | 5 years | 6 years | 2 years | 4 years ^a |

NOTE.— = absent; + = present; ± = probably present; GTCS = generalized tonic-clonic seizures; GCS = generalized clonic seizures; GTS = generalized tonic seizures; Abs = absence seizures; SPS = simple partial seizures; CPS = complex partial seizures.

^a Died at age 4 years.

with a toxic increase in function. In this respect, it is of interest that heterozygous knockout mice for three voltage-gated sodium-channel α -subunits (*SCN2A*^{+/-}, *SCN8A*^{+/-}, and *SCN10A*^{+/-}) do not display an abnormal phenotype and appear to develop normally. In contrast, homozygous knockout mice for these genes have a severe phenotype. *SCN2A*^{-/-} mice die, as a result of severe hypoxia and extensive neuronal cell death, within 1–2 d of birth (Planells-Cases et al. 2000). *SCN8A*^{-/-} mice display a paralytic phenotype, with muscle atrophy and ataxia, and die \leq 4 wk after birth (Burgess et al. 1995). *SCN10A* is a sensory-neuron-specific voltage-gated sodium channel. *SCN10A*^{-/-} mice have partial deficits in perception of noxious thermal, mechanical, and inflammatory stimuli (Akopian et al. 1999). Given these observations, we conclude that the analysis of mutant transcripts and proteins is necessary for elucidation of the exact pathogenetic mechanism of heterozygous *SCN1A* mutations in patients with SMEI.

Acknowledgments

The authors thank the patients and their relatives for their cooperation and participation in this study. We are grateful to Hubert Backhovens, Dirk Van Den Bossche, and Sam Sluijs,

for expert technical assistance, and to Dirk Snyders, for interesting and helpful discussions. This research was supported by the Fund for Scientific Research–Flanders (FWO-Belgium). L.C. is funded by a doctoral fellowship from the University of Antwerp.

Electronic-Database Information

Accession numbers and URLs for data in this article are as follows:

Genbank, <http://www.ncbi.nlm.nih.gov/Genbank> (for genomic clone containing *SCN1A* [accession number AC010127], human *SCN1A* [for cDNA accession number AF225985, for protein accession number AAK00217], *Rattus norvegicus Scn1a* [accession number AAA79965], human *SCN2A* [accession number NP_066287], human *SCN3A* [accession number AAK00219], *Rattus norvegicus Scn3a* [accession number NP_037251], human *SCN4A* [accession number NP_000325], human *SCN5A* [accession number NP_000326], human *SCN6A* [accession number NP_002967], human *SCN8A* [for cDNA accession number XM_006838, for protein accession number XP_006838], human *SCN9A* [accession number NP_002968], human *SCN10A* [accession number NP_006505], human *SCN11A* [accession number AAF17480], human *SCN12A* [accession number NP_054858], *Takifugu rubripes* [accession number

BAA07195], *Loligo opalescens* [accession number AAA16202], *Electrophorus electricus* [accession number CAA25587], *Drosophila melanogaster* [accession number AAB59192])
 Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for GEFS+ [MIM 604233])
 Primer3 program, http://www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi
 CEPH genotype database, <http://www.cephb.fr/cephdb/dumps.html>

References

- Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, Smith A, Kerr BJ, McMahon SB, Boyce S, Hill R, Stanfa LC, Dickenson AH, Wood JN (1999) The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. *Nat Neurosci* 2:541–548
- Alderborn A, Kristofferson A, Hammerling U (2000) Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. *Genome Res* 10:1249–1258
- Burgess DL, Kohrman DC, Galt J, Plummer NW, Jones JM, Spear B, Meisler MH (1995) Mutation of a new sodium channel gene, *Scn8a*, in the mouse mutant “motor endplate disease.” *Nat Genet* 10:461–465
- Commission on Classification and Terminology of the International League Against Epilepsy (1989) Proposal for revised classification of epilepsies and epileptic syndromes. *Epilepsia* 30:389–399
- den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 15:7–12
- Dravet C (1978) Les épilepsies graves de l'enfant. *Vie Med* 8: 543–548
- Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-Gourfinkel I, Brice A, LeGuern E, Moulard B, Chaigne D, Buresi C, Malafosse A (2000) Mutations of *SCN1A*, encoding a neuronal sodium channel, in two families with GEFS+2. *Nat Genet* 24:343–345
- Escayg A, Heils A, MacDonald BT, Haug K, Sander T, Meisler MH (2001) A novel *SCN1A* mutation associated with generalized epilepsy with febrile seizures plus—and prevalence of variants in patients with epilepsy. *Am J Hum Genet* 68: 866–873
- Planells-Cases R, Caprini M, Zhang J, Rockenstein EM, Rivera RR, Murre C, Masliah E, Montal M (2000) Neuronal death and perinatal lethality in voltage-gated sodium channel α_1 -deficient mice. *Biophys J* 78:2878–2891
- Schaller KL, Krzemien DM, McKenna NM, Caldwell JH (1992) Alternatively spliced sodium channel transcripts in brain and muscle. *J Neurosci* 12:1370–1381
- Scheffer IE, Berkovic SF (1997) Generalized epilepsy with febrile seizures plus: a genetic disorder with heterogeneous clinical phenotypes. *Brain* 120:479–490
- Underhill PA, Jin L, Lin AA, Mehdi SQ, Jenkins T, Vollrath D, Davis RW, Cavalli-Sforza LL, Oefner PJ (1997) Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. *Genome Res* 7:996–1005
- Wallace RH, Scheffer IE, Barnett S, Richards M, Dibbens L, Desai RR, Lerman-Sagie T, Lev D, Mazarib A, Brand N, Ben-Zeev B, Goikhman I, Singh R, Kremmidoitis G, Gardner A, Sutherland GR, George AL Jr, Mulley JC, Berkovic SF (2001) Neuronal sodium-channel α_1 -subunit mutations in generalized epilepsy with febrile seizures plus. *Am J Hum Genet* 68:859–865
- Wang SY, Cruts M, Del-Favero J, Zhang Y, Tissir F, Potier MC, Patterson D, Nizetic D, Bosch A, Chen H, Bennett L, Estivill X, Kessling A, Antonarakis SE, Van Broeckhoven C (1999) A high-resolution physical map of human chromosome 21p using yeast artificial chromosomes. *Genome Res* 9:1059–1073